EXECUTIVE ENGAGEMENTS
POOL
4521
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
814
Interactions with Platform & by Email
PARTICIPANTS
136
Unique # Participated
VALIDATIONS
39
Responses Validated*
COMPANIES
38
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
54
PAGES
122
EDITION
18
PRICE
USD 5600
CODE
MCP-6433
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Endometriosis Drugs estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$2.2 Billion by 2027, growing at aCAGR of 2.8% over the period 2020-2027. Hormone therapy, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Analgesics segment is readjusted to a revised 2.5% CAGR for the next 7-year period.
The Endometriosis Drugs market in the U.S. is estimated at US$524.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$387.4 Million by the year 2027 trailing a CAGR of 2.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 2.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
SELECT PLAYERS
AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca Plc; Bayer AG; Debiopharm Group; Evotec AG; Kissei Pharmaceutical Co. Ltd.; Neurocrine Biosciences Inc.; ObsEva SA; Pfizer Inc.; Repros Therapeutics Inc.; Takeda Pharmaceutical Company Limited; ValiRx plc
SEGMENTS
» Product Type (Hormone therapy, Analgesics)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Endometriosis: An Introductory Prelude |
| Recent Market Activity |
| Endometriosis Facts in a Nutshell |
| Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs |
| Key Endometriosis Drugs on the Market |
| The Pipeline Review |
| Key Endometriosis Drugs in the Pipeline: 2017 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| AbbVie Inc. (USA) |
| Astellas Pharma Inc. (Japan) |
| AstraZeneca Plc (UK) |
| Bayer AG (Germany) |
| Debiopharm Group (Switzerland) |
| Evotec AG (Germany) |
| Kissei Pharmaceutical Co., Ltd. (Japan) |
| Neurocrine Biosciences, Inc. (USA) |
| ObsEva SA (Switzerland) |
| Pfizer, Inc. (USA) |
| Repros Therapeutics, Inc. (USA) |
| Roivant Sciences GmbH (Switzerland) |
| Takeda Pharmaceutical Company Limited (Japan) |
| ValiRx plc (UK) |
| 3. MARKET TRENDS & DRIVERS |
| Steady Growth Expected Over the Next Few Years |
| Emerging Treatment for Endometriosis & Endometrial Cancer |
| Global Awareness Campaigns and Efforts |
| Uptrend in Healthcare Expenditure Creates Substantial Opportunities |
| Developed Regions Remain Primary Revenue Contributors |
| Developing Regions Exhibit Immense Growth Potential |
| Stable Economic Scenario to Augment Market Prospects |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 38 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com